Envista (NYSE:NVST) Stock Price Expected to Rise, Barclays Analyst Says

Envista (NYSE:NVST) had its target price increased by equities research analysts at Barclays from $24.00 to $34.00 in a research note issued to investors on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price objective suggests a potential upside of 18.34% from the company’s current price.

Several other brokerages have also recently weighed in on NVST. Mizuho upped their price target on Envista from $24.00 to $27.00 and gave the company a “neutral” rating in a research report on Tuesday. Wall Street Zen raised shares of Envista from a “buy” rating to a “strong-buy” rating in a research note on Monday, January 26th. Weiss Ratings reiterated a “sell (d)” rating on shares of Envista in a research note on Monday, December 29th. William Blair raised shares of Envista from a “hold” rating to an “outperform” rating in a report on Friday, February 6th. Finally, Evercore reaffirmed an “outperform” rating and issued a $32.00 price target on shares of Envista in a report on Friday, February 6th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $27.43.

Envista Trading Down 5.1%

Shares of NVST stock opened at $28.73 on Wednesday. The stock has a market capitalization of $4.72 billion, a price-to-earnings ratio of 102.61, a PEG ratio of 2.07 and a beta of 1.01. The company’s fifty day simple moving average is $23.54 and its two-hundred day simple moving average is $21.48. Envista has a 1 year low of $14.22 and a 1 year high of $30.42. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.38 and a quick ratio of 2.04.

Envista (NYSE:NVST) last announced its quarterly earnings results on Thursday, February 5th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of $0.32 by $0.06. Envista had a return on equity of 6.54% and a net margin of 1.73%.During the same period in the previous year, the firm earned $0.24 earnings per share. The business’s revenue for the quarter was up 15.0% compared to the same quarter last year. Envista has set its FY 2026 guidance at 1.350-1.450 EPS. As a group, analysts anticipate that Envista will post 1 earnings per share for the current year.

Insider Activity

In related news, SVP Mischa Reis sold 9,675 shares of the company’s stock in a transaction on Tuesday, February 10th. The shares were sold at an average price of $30.00, for a total value of $290,250.00. Following the completion of the transaction, the senior vice president directly owned 32,382 shares in the company, valued at approximately $971,460. The trade was a 23.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.66% of the company’s stock.

Institutional Investors Weigh In On Envista

Several hedge funds have recently added to or reduced their stakes in the company. Farther Finance Advisors LLC boosted its holdings in shares of Envista by 317.6% in the 3rd quarter. Farther Finance Advisors LLC now owns 1,349 shares of the company’s stock worth $27,000 after purchasing an additional 1,026 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its position in Envista by 16,711.1% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock worth $31,000 after buying an additional 1,504 shares during the last quarter. Allworth Financial LP lifted its position in Envista by 75.4% in the 4th quarter. Allworth Financial LP now owns 1,805 shares of the company’s stock worth $39,000 after buying an additional 776 shares during the last quarter. IFP Advisors Inc boosted its stake in Envista by 102.9% in the fourth quarter. IFP Advisors Inc now owns 2,112 shares of the company’s stock worth $46,000 after buying an additional 1,071 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Envista by 73.1% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock valued at $44,000 after acquiring an additional 949 shares during the last quarter.

Key Stories Impacting Envista

Here are the key news stories impacting Envista this week:

• Positive Sentiment: Q4 EPS and revenue beat drove early upside — Zacks reports NVST jumped after the quarter as EPS and revenue topped expectations and segments showed double-digit growth despite margin pressure. Read More.
• Positive Sentiment: Barclays raised its price target to $34 and moved the stock to “overweight,” giving Wall Street momentum and a stronger institutional narrative behind the rally. Read More.
• Positive Sentiment: Broker recognition: NVST was added to Zacks’ top growth list (Zacks Rank #1), which can attract momentum and growth-focused flows. Read More.
• Neutral Sentiment: Mizuho nudged its target higher to $27 but kept a neutral rating — a modest endorsement that is less bullish than some peers and may temper further upside. Read More.
• Negative Sentiment: Underlying profitability concerns: a Quiver summary shows Q4 revenue grew modestly, but Envista reported a large operating loss (~$337M) and net loss (~$372M), which weighs on the sustainability of the EPS beat and investor confidence. Cash remains healthy, but the losses are a material negative. Read More.
• Negative Sentiment: Insider and institutional selling: SVP Mischa Reis disclosed a sale (~9,675 shares) and major funds have trimmed stakes recently (e.g., Morgan Stanley, BlackRock, Point72), which can pressure the stock and prompt profit-taking. Read More. • Read More.

Envista Company Profile

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.